Peer-reviewed veterinary case report
Intranasal cat vaccine reduces symptoms from Bordetella
By Bradley, A et al.·Published in Journal of veterinary internal medicine·2012·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of intranasal administration of a modified live feline herpesvirus 1 and feline calicivirus vaccine against disease caused by Bordetella bronchiseptica after experimental challenge.
- Species:
- cat
Plain-English summary
Ten 12-week-old kittens were given an intranasal vaccine for feline herpesvirus and calicivirus, then exposed to Bordetella bronchiseptica, a bacteria that can cause respiratory illness. The vaccinated kittens showed fewer signs of illness compared to those that did not receive the vaccine, with significantly less sneezing and overall clinical symptoms in the first ten days after exposure. This suggests that the vaccine not only protects against the viruses it targets but may also help reduce illness from other infections.
People also search for: kitten sneezing treatment · Bordetella bronchiseptica in cats · feline herpesvirus vaccine effectiveness
Abstract
BACKGROUND: Studies suggest that intranasal vaccination can stimulate nonspecific immunity against agents not contained within the vaccine, but this effect is not reported for cats. HYPOTHESIS: A modified live feline herpesvirus-1 (FHV-1) and feline calicivirus (FCV) intranasal vaccine will reduce clinical signs of disease caused by experimental infection with Bordetella bronchiseptica. ANIMALS: Twenty specific pathogen-free 12-week-old kittens. METHODS: Experimental study. Cats were randomized into 2 groups of 10 cats each. The vaccinated group was administered a single intranasal dose of a commercially available vaccine containing modified live strains of FHV-1 and FCV, and the control group remained unvaccinated. All 20 cats were administered B. bronchiseptica by nasal inoculation 7 days later and were observed daily for clinical signs of illness for 20 days. RESULTS: In the first 10 days after B. bronchiseptica challenge, vaccinated cats were less likely to be clinically ill than control cats with a median clinical score of 0/180 (range 0-5) versus 2/180 (range 0-8) (P = .01). Nine of 10 control cats and 2 of 10 vaccinated cats were recorded as sneezing during days 1-10 after challenge (P = .006). CONCLUSIONS AND CLINICAL IMPORTANCE: Intranasal vaccination against FHV-1 and FCV decreased signs of illness due to an infectious agent not contained in the vaccine. This nonspecific immunity could be beneficial for protection against organisms for which vaccines are not available and as protection before development of vaccine-induced humoral immunity.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22860699/